CBL-B, His-Avi-Tag, Biotin-labeled (Human) Recombinant

Only %1 left

Catalog #

80412

As low as $315 *

Cat # Size Price*

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant human CBL-B (Cbl proto-oncogene B) encompassing amino acids 39-426 (contains the SH2-like domain). This construct contains a His-tag (6xHis) followed by an Avi-Tag™, linked to the N-terminal end of the protein. The recombinant protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.

●

Synonyms

E3 ubiquitin-protein ligase CBL-B, RING finger protein 56, SH3- binding protein CBL-B, CBL, CBLB, Casitas B-lineage lymphoma proto-oncogene b, RNF56, RING-type E3 ubiquitin transferase CBL-B, Nbla00127

●

Product Data Gallery

4-20% SDS-Page Coomassie Staining

Biotin-Avidin Pulldown

Product Info

Storage and Usage

Citations

Species

Human

Construct

CBL-B (His-Avi-39-426)-(Biotin)

Host Species/Expression System

E. coli

Purity

≥90%

Format

Aqueous buffer solution

Formulation

45 mM Tris-HCl pH 8.0, 124 mM NaCl, 2.4 mM KCl, 10% glycerol, 3 mM DTT

48 kDa

Amino Acids

39-426

Genbank #

NM_170662

UniProt #

Q13191

Tag(s)

N-terminal His-Avi Tag

Label

This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%.

For more information on enzymatic biotinylation, please see our Tech Note.

Background

CBL-B, a RING finger E3-ubiquitin ligase, acts as an intracellular checkpoint and a regulator of cytotoxic lymphocytes and NK cells. CBL-B binds E2-ubiqutin as well as target proteins such as TAM receptor TYRO3, forcing further degradation of TYRO3. CBL-B modulates innate immune responses and plays a key role in host defense to pathogens and anti-tumor immunity. Targeting CBL-B represents a potential therapeutic strategy for the management of human immune-related disorders such as autoimmune diseases, infections, tumors, and allergic airway inflammation. CBL-B has emerged as a new target of interest in the field of immunotherapy due to its ability to suppress cancer immune-evasion. CBL-B initiates anti-cancer immune responses in NK cells in both cytotoxic and effector T cells, promoting T-cell and NK cell activation.

References

1. Jeon, M.S., et al., Immunity. 2004; 21(2): 167-177.
2. Chiang, Y.J. et al., Nature. 2000; 403: 216-220.

Skip to the end of the images gallery

Skip to the beginning of the images gallery

●

Datasheets/Protocols

80412 Lot 211008-G

Datasheets provide example lot-specific information. Contact us to request information on currently available lots.

● General Protocols

● FAQs

● Contact Technical Service

●

CBL-B, His-Avi-Tag, Biotin-labeled (Human) Recombinant

PRODUCTS

SERVICES

RESOURCES

COMPANY